Showing recent highlights
What's New
PubMed · June 3, 2026
Researchers found that artificial intelligence (AI) tools — specifically a type called machine learning, where computers learn to spot patterns in medical data — can detect fatty liver disease with a fairly high level of accuracy, correctly identifying the condition about 80–88% of the time across different tests. The results were even better when these AI tools were paired with imaging scans like ultrasounds or MRIs, suggesting that combining smart computer analysis with medical imaging could one day help doctors catch fatty liver disease without needing a painful liver biopsy (where a small piece of liver tissue is removed and examined). This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed (Guideline Reviews) · June 1, 2026
According to the 2026 clinical practice guidelines for fatty liver disease (a condition where fat builds up in the liver and can cause serious damage over time), doctors are recommended to use a simple blood test calculation called the FIB-4 index as a first step to check how much scarring — called fibrosis — may be developing in the liver. If that result raises concern, guidelines recommend following up with an imaging test called elastography, which measures liver stiffness, and referring the patient to a liver specialist. This matters because catching liver scarring early is the most important factor in preventing serious complications down the road.
Ask your doctor: Ask the doctor whether the patient should have any special tests to check if fatty liver disease is causing damage to the liver, or if the patient needs to see a liver specialist.
What's New
PubMed · June 1, 2026
A study found that people with fatty liver disease who followed a low glycemic index diet — meaning foods that raise blood sugar more slowly, like whole grains, legumes, and most fruits — showed a noticeable reduction in liver fat compared to those eating a diet of foods that spike blood sugar quickly. Researchers also observed improvements in blood sugar control, body weight, and levels of inflammation in the body, which is important because ongoing inflammation can make fatty liver disease worse over time. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · June 1, 2026
According to Italian Society of Gastroenterology (SIGE) guidelines, a diabetes medication like Ozempic or Victoza can be safely used by people with type 2 diabetes or obesity who also have liver or digestive conditions, and there is no need to stop taking it before a routine stomach scope procedure. The guidelines also note that these medications do not appear to raise the risk of cancers in the stomach, colon, or pancreas, and may even lower the chances of a specific type of liver cancer. People taking this type of medication may experience mild, temporary digestive side effects — like nausea or stomach upset — and a higher chance of developing gallstones (hard deposits that form in the gallbladder), but serious digestive complications do not appear to be a concern.
Lifestyle
PubMed · June 1, 2026
A study found that people with fatty liver disease (a condition where excess fat builds up in the liver) who gradually increased their daily steps — eventually doubling them, from about 5,000 to over 10,000 steps a day — while also doing resistance training (like weightlifting or strength exercises) over 16 weeks showed meaningful improvements in brain blood flow and cognitive function, meaning their thinking and mental sharpness got better. Researchers also found improvements in how stiff the arteries were and in markers of liver health. The exercise group followed this routine alongside a calorie-reduced diet, and more than 80% of participants stuck with the program throughout the study.
What's New
PubMed · May 29, 2026
Researchers found that a simple calculation using blood sugar and triglyceride (a type of fat in the blood) levels — called the TyG index — may help identify people at higher risk for fatty liver disease. Looking at data from over 212,000 people across 19 studies, higher TyG index scores were linked to worse fatty liver outcomes, suggesting this easy-to-measure marker could be a useful early warning sign. This is early research and hasn't yet changed treatment guidelines.
What's New
ScienceDaily · May 27, 2026
Scientists at UC San Diego have announced an experimental drug called ION224 that may help treat a serious form of fatty liver disease — a condition where fat builds up in the liver and causes inflammation and damage over time. In early testing, people with this condition showed notable improvements in their liver health after taking the drug, even without losing weight. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 8, 2026
Researchers found that taking curcumin — the active compound in turmeric — did not meaningfully reduce body weight, waist size, or body mass index (a measure of body fat based on height and weight) in people with fatty liver disease. This matters because many people with fatty liver disease are looking for supplements that might help alongside lifestyle changes, and these results suggest curcumin may not move the needle on body measurements. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · May 8, 2026
Researchers found that for adults with fatty liver disease, eating freshwater fish regularly and consuming yogurt enriched with vitamin D and probiotics (live beneficial bacteria) consistently helped improve blood sugar control and cholesterol levels. Fish oil and omega-3 supplements also showed modest improvements in cholesterol and liver health markers, while red meat showed mixed results depending on how much was eaten and what else was in a person's diet.
What's New
PubMed · May 1, 2026
Researchers found that a diabetes medication like Ozempic or Victoza, which is also used to help people lose weight, did not appear to cause significant muscle loss or weakness in people with fatty liver disease — a condition where extra fat builds up in the liver. This matters because losing muscle is a real concern with rapid weight loss, and people with fatty liver disease are already at higher risk for muscle problems. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 1, 2026
Researchers found that two newer treatments for fatty liver disease — Efruxifermin and Resmetirom — both helped reduce the amount of fat built up in the liver, but Efruxifermin appeared to reduce liver fat more significantly in these studies, and it also helped lower a key marker of liver inflammation (a liver enzyme called AST) as well as fats in the blood called triglycerides. This matters because fatty liver disease can silently progress into serious scarring of the liver (cirrhosis) or even liver cancer if left unchecked, so finding treatments that can reverse some of that damage is a big deal for people living with this condition. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 1, 2026
Researchers found that a supplement called essential phospholipids — a type of fat molecule that helps protect liver cells — reduced fat buildup in the livers of people with fatty liver disease over six months compared to a placebo (a dummy pill with no active ingredient). People taking the supplement also reported feeling less fatigued and saw improvements in their blood sugar level (A1C), which measures how well blood sugar has been managed over the past few months. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · May 1, 2026
According to the Italian Association for the Study of the Liver (AISF) guidelines, people with fatty liver disease — especially those who also have type 2 diabetes, obesity, or metabolic syndrome — should be carefully identified, evaluated, and monitored for newer treatments that have shown real promise in slowing liver damage. The guidelines highlight two medications, Resmetirom and Semaglutide (a diabetes medication like Ozempic or Victoza), as the first to show meaningful improvements in liver tissue in clinical testing for patients with more advanced liver inflammation and scarring. This matters because, without proper care, fatty liver disease can progress to serious conditions like cirrhosis (severe liver scarring), liver cancer, or serious heart problems like heart attacks or strokes.
Ask your doctor: Ask the doctor whether the patient should learn about Resmetirom or Semaglutide, since these are newer medications that have shown they can actually improve fatty liver disease in studies.
Guidelines
PubMed · May 1, 2026
According to the American Association for the Study of Liver Diseases (AASLD) guidelines, Wegovy — a diabetes and weight-loss medication whose active ingredient is semaglutide — is now recommended as a treatment option for people with a serious form of fatty liver disease called MASH, specifically those whose liver scarring has reached a moderate-to-advanced stage. The guidelines note that doctors can identify the right candidates using non-invasive liver scans and tests rather than a liver biopsy, making it easier for more patients to access this treatment. This matters because untreated liver scarring can progress over time, and having a now FDA-approved medication option gives doctors and patients a meaningful new tool to help slow that damage.
Ask your doctor: Ask the doctor whether the patient might benefit from trying Wegovy injections for their fatty liver disease, especially since the FDA just approved it for this condition.
What's New
PubMed · May 1, 2026
Researchers found that taking a daily supplement made from polysaccharides — complex sugars found in plants — may help improve certain liver enzyme levels in people with fatty liver disease, a condition where too much fat builds up in the liver. The supplement also appeared to shift the balance of bacteria living in the gut, which some scientists believe plays a role in liver health. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 1, 2026
A study found that a traditional Chinese herbal formula called Yinchenhao Decoction (YCHD) may help people with fatty liver disease — a condition where too much fat builds up in the liver. After 24 weeks, people taking YCHD had meaningful reductions in the amount of fat in their liver, as well as improvements in liver health markers and body weight, compared to those taking a placebo (a dummy treatment with no active ingredients). This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · April 16, 2026
A study found that people with fatty liver disease who ate about 400 grams of Navelina oranges — roughly two medium oranges — every day for four weeks showed changes in certain fats circulating in their blood, including shifts in fatty acids that are linked to HDL (often called 'good' cholesterol). Researchers found correlations suggesting that some of these fatty acid changes may be connected to improvements in liver fat buildup, though the overall differences between the orange-eating group and the comparison group were not statistically significant. This was one of the first studies to look closely at how this specific type of orange might affect blood fat patterns in people with fatty liver disease.
What's New
PubMed · April 4, 2026
Researchers found that people with gum disease (a condition where bacteria inflame and damage the gums and bone around the teeth) were about 34% more likely to also have fatty liver disease, based on data from over 225,000 people across 11 studies. The research also hinted that the relationship may go both ways — meaning fatty liver disease might also raise the chances of developing gum disease — though that part of the evidence is still limited. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 1, 2026
A study found that a medication called saroglitazar, when added to lifestyle changes like diet and exercise, did not reduce liver fat significantly more than lifestyle changes alone in people with fatty liver disease who were not overweight or obese. Both groups did see some improvement in their liver fat levels over six months, which suggests that lifestyle changes can still help even in people who aren't carrying extra weight — a group that's often overlooked in fatty liver research. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · April 1, 2026
A study found that people with fatty liver disease (a condition where fat builds up in the liver and can cause scarring over time) can be better sorted into low-risk and high-risk groups using simple, non-invasive tests — meaning tests that don't require surgery or a tissue sample. Researchers looked at nine studies and found that these testing pathways helped doctors figure out who truly needed a specialist visit and who could safely be monitored closer to home, avoiding unnecessary trips to a liver specialist. This matters because catching serious liver scarring early can make a real difference in outcomes, so people with fatty liver disease — especially those who also have type 2 diabetes — may want to ask their doctor whether they've been assessed for liver scarring and what tests might be appropriate for them.
What's New
PubMed · April 1, 2026
Researchers found that taking vitamin D supplements may help people with fatty liver disease by lowering blood sugar levels, reducing insulin resistance (when the body doesn't respond well to insulin), lowering certain fats in the blood called triglycerides, and reducing liver inflammation — while also raising 'good' HDL cholesterol. These are all markers that doctors watch closely in people with fatty liver disease, so improvements across several of them at once is considered a noteworthy finding. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · April 1, 2026
Researchers found that among different types of exercise studied in people with fatty liver disease, high-intensity interval training — short bursts of hard effort followed by rest, repeated several times — showed the strongest results for reducing fat stored inside the liver, followed by steady aerobic exercise like brisk walking or cycling. Exercise in general also helped lower fasting blood sugar (the amount of sugar in the blood after not eating) and improved markers that doctors use to check how well the liver is working.
What's New
PubMed · April 1, 2026
Researchers found that a type of ultrasound scan called attenuation imaging can accurately detect and measure fat buildup in the liver — which is a key feature of fatty liver disease. This matters because the most accurate current method uses a specialized MRI scan that can be expensive and less widely available, while ultrasound is cheaper and easier to access at most clinics. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · April 1, 2026
A study found that time-restricted eating — limiting all meals and snacks to a set window of hours each day (typically 8 hours or less) and fasting the rest of the time — led to meaningful reductions in body weight, waist size, and body fat in overweight and obese adults. Researchers also found modest improvements in insulin resistance (a condition where the body struggles to use insulin properly to manage blood sugar, which can raise the risk of type 2 diabetes). The findings came from pooling results across 28 separate studies involving 1,648 participants, though the researchers noted that results varied depending on the individual and how the eating window was structured.
What's New
PubMed · April 1, 2026
Researchers found that people with fatty liver disease who took semaglutide — a diabetes medication like Ozempic or Victoza — showed meaningful improvements in liver health compared to those who took a placebo, including reductions in liver fat and improvements in blood sugar level (A1C) and cholesterol over 52 weeks. The study also used non-invasive tests (simple scans and blood tests, rather than a liver biopsy) to track these changes, which could make it easier to monitor fatty liver disease in the future without uncomfortable procedures. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 31, 2026
Researchers found that taking alpha-lipoic acid (ALA) — a popular antioxidant supplement — did not improve liver health, blood sugar control, cholesterol, or weight-related measures in people with fatty liver disease (a condition where too much fat builds up in the liver). This held true across different doses, ages, and study lengths when researchers analyzed seven studies involving 414 people. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 5, 2026
Researchers found that a supplement called Ganwei — which works by activating a specific liver enzyme — showed promising signs of reducing fat buildup in the liver in people with a condition called fatty liver disease (where excess fat collects in the liver and can cause long-term damage). Interestingly, the combination of Ganwei with metformin, a common diabetes medication, did not show the same improvement, suggesting Ganwei may work better on its own. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · March 4, 2026
A study found that in people with high blood pressure, keeping blood pressure below 130/80 mmHg significantly reduced the risk of serious heart problems like heart attacks or strokes — and this benefit was just as strong in people who also had a fatty liver condition (where fat builds up in the liver, which can raise heart risk) as in those without it. The study followed nearly 30,000 adults in rural China over four years. People with high blood pressure and a fatty liver condition may want to ask their doctor whether tighter blood pressure management could be right for them.
Lifestyle
PubMed · March 1, 2026
A study found that people with fatty liver disease who did treadmill workouts three times a week for six months — either short bursts of intense effort (called high-intensity interval training) or a steady moderate-paced session of 30–40 minutes — both saw meaningful reductions in fat buildup in their liver. Researchers found that both approaches worked equally well for the liver itself, suggesting that simply showing up and exercising regularly matters more than how hard a person pushes. The higher-intensity interval workouts did provide an added bonus: greater improvement in cardiorespiratory fitness, meaning the heart and lungs got stronger at delivering oxygen during activity.
Lifestyle
PubMed · March 1, 2026
Researchers found that people with fatty liver disease — a condition where fat builds up in the liver and can cause damage over time — lost more weight when their lifestyle program included digital support tools like text messages, phone or video check-ins, or smartphone apps that helped them eat better and move more. Losing around 7% to 10% of body weight is known to reduce fat in the liver and lower the risk of further liver damage, and the studies found these tech-assisted programs produced meaningful, though moderate, weight loss compared to programs without that support. How long the program lasted also mattered — longer interventions tended to produce better results.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.